Skip to main content
OpenTrials
Completed

NCT Number: NCT07042204

Effectiveness of E-prf Alone and in Combination With Bioactive Glass Nanoparticles in Grade II Furcation Defects

The aim of the study is to evaluate and compare the effectiveness of extended platelet-rich fibrin (ePRF) alone and in combination with bioactive glass nanoparticles in the treatment of grade II furcation defects clinically and radiographically.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Furcation Defects Mouth Diseases Periodontal Diseases Stomatognathic Diseases

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mansoura University

Al Mansurah, 35516, Egypt

About this study

A total of 30 grade II furcation defects will be randomly divided into three groups as follows:

Group I: 10 grade II furcation defects will be treated by extended platelet-rich fibrin (ePRF) alone.

Group II: 10 grade II furcation defects will be treated by bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF).

Group III: 10 grade II furcation defects will be treated by bioactive glass nanoparticles with collagen membrane.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Presence of Glickman's grade II furcation defects in molars probing depth (PD) ≥5 mm horizontal PD ≥3 mm.
  • The patients are in good systemic health and had not undergone any periodontal surgery in the areas to be treated within the prior 12 months.

Exclusion criteria

  • Smokers and tobacco chewers.
  • Patients that take any medications within the past 6 months that could alter their periodontal status.
  • pregnant or lactating females.
  • Patients with known allergy to materials or drugs that will be used or prescribed in this study.

Treatment and study plan

Group I (extended platelet-rich fibrin)

Procedure

mucoperiosteal flap will be raised through sulcular incisions Debridement of granulation tissue from the osseous defect and furcation will be filled with (ePRF) at the first group

Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin)

Procedure

bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF)

Group III (bioactive glass nanoparticles and covered by a collagen membrane)

Procedure

bioactive glass nanoparticles and covered by a collagen membrane

Primary outcomes

  1. The primary outcome will be the amount of bone fill vertically and horizontally obtained in the treatment of grade II furcation defects calculated from CBCT data in millimeters

    Time frame: 6 months follow up

Secondary outcomes

  1. the secondary outcomes include improvements (decrease)of probing depth in millimetres

    Time frame: 3 and 6 months follow up

    Using UNC-15 periodontal probe to measure the probing depth from the base of the pocket to the free gingival margin. All measurements will be rounded off to the nearest millimetre.

  2. the secondary outcomes include improvements (decrease)of clinical attachment level loss in millimetres

    Time frame: 3 and 6 months follow up

    using a UNC-15 periodontal probe to measure clinical attachment level loss from the cemento-enamel junction (CEJ) to the pocket depth. All measurements will be rounded off to the nearest millimetre

  3. the secondary outcomes include improvements (decrease) of gingival recession measured in millimetres

    Time frame: 3 and 6 months follow up

    Using a UNC-15 periodontal probe to measure gingival recession from cemento-enamel junction (CEJ) to the free gingival margin. All measurements will be rounded off to the nearest millimetre

  4. the secondary outcomes include improvements (decrease) of gingival bleeding index

    Time frame: 3 and 6 months follow up

    It's performed through gentle probing of the orifice of the gingival crevice using a UNC-15 periodontal probe. If bleeding occurs within 10 seconds a positive finding is recorded, and the number of positive sites is recorded and then expressed as a percentage of the number of the sites examined.

Sponsors and collaborators

Lead sponsor

Merna Nasser Mohamed Mostafa Ibrahim Elnahas

Other

Registry information

Official study title

Effectiveness of Extended Platelet-Rich Fibrin (ePRF) Alone and in Combination With Bioactive Glass Nanoparticles in the Treatment of Grade II Furcation Defects

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jun 27, 2025
Registry last updated
Jan 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.